FDA Approves Combination Therapy Juvisync
Links shared publicly online about this topic.
- 0total visits
FDA Approves Combination Therapy Juvisync
View full resource at drugs.com
Tags: Cholesterol, Cholesterol Medication, Diabetes Type 2 Medication, Drug, FDA, Zocor, Januvia
Most Recently Shared on October 7, 2011 at 7:01 pm By:
FDA Approves Combination Therapy Juvisync: SILVER SPRING, Md., Oct. 7, 2011 /PRNewswire-USNewswire/ -- The... http://t.co/p0IghJRL #drug
Evidence In Medicine - Not so SHARP
evidenceinmedicine.org — “I've written a bit previously in this blog about the evidence around lipid-lowering therapies, and in particular about the lack of evidence for combining other lipid-lowering therapies, including ezetimibe, with statins. Tomorrow, the FDA will apparently be taking up a request to approve Vytorin (simvastatin/ezetimibe) for the treatment of patients with chronic kidney disease (CKD). As a result of this request for approval, we also have access to the FDA review of data from the SHARP trial. SHAR” View full resource at evidenceinmedicine.org
Most Recently Shared on November 2, 2011 at 12:45 am By:
David Rind Physician, Doctor, and Internist
Not so SHARP http://t.co/qLxc6uoD
FDA clears Merck type 2 diabetes medication - Pharmaceutical Technology
pharmaceutical-technology.com — “The US Food and Drug Administration (FDA) has approved Merck's Juvisync, a once-daily therapy for type 2 diabetes that combines glucose-lowering medication sitagliptin, the active component of Januvia, with cholesterol-lowering medication...” View full resource at pharmaceutical-technology.com
Most Recently Shared on October 12, 2011 at 10:25 pm By:
FDA clears Merck type 2 diabetes medication: The US Food and Drug Administration (FDA) has approved Merck's Juvi... http://t.co/Jgy4ezr9
FDA approves combination therapy Juvisync
fda.gov — “The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.” View full resource at fda.gov
Most Recently Shared on October 12, 2011 at 9:49 pm By:
HeartofDiabetes Health Organization
FDA approves combination therapy Juvisync, the first combination drug to treat type 2 diabetes and high... http://t.co/JAiPnkZA
Two-Drug Tablet for Diabetics with High Cholesterol Approved - Renal and Urology News
renalandurologynews.com — “The FDA has approved Juvisync, a combination prescription medication for patients with both type 2 diabetes and high cholesterol.” View full resource at renalandurologynews.com
Most Recently Shared on October 12, 2011 at 4:11 pm By:
Renal Urology News Urology, Medical Publisher, Health News, and Nephrology
Two-Drug Tablet for Diabetics with High Cholesterol Approved. http://t.co/AM8JSC4f #FDA #News #Drugs #Diabetes #Cholesterol
FDA OKs diabetes, cholesterol combo drug - Related Stories - DiabetesPro SmartBrief
smartbrief.com — “Merck & Co. secured marketing approval from the FDA for Juvisync, a treatment containing the firm's type 2 diabetes pill Januvia and cholesterol-lowering statin simvastatin. The combination was approved for marketing in multiple strengths. "Dose selection should factor in what other drugs the patie…” View full resource at smartbrief.com
Most Recently Shared on October 10, 2011 at 4:03 pm By:
Jill Weisenberger Nutritionist and Dietitian
Available in 6 dosages RT @Eatingsoulfully: FDA OKs diabetes, cholesterol combo drug http://t.co/5Wp37M2a #diabetes
FDA Approves Juvisync for Diabetes, High Cholesterol : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on October 7, 2011 at 7:46 pm By:
Bob Finn - Medical News Net Health News
FDA approves Juvisync, the first product to combine a drug for type 2 diabetes with a cholesterol-lowering drug - http://t.co/Mfbtsp03
Sitagliptin And Simvastatin Combination - Juvisync - Approved By FDA For Diabetes With High Cholesterol
medicalnewstoday.com — “The first single tablet for both diabetes type 2 and high cholesterol, Juvisync (sitagliptin and simvastatin), has been approved by the FDA (Food and Drug Administration). Sitagliptin and simvasta” View full resource at medicalnewstoday.com
Most Recently Shared on October 7, 2011 at 7:05 pm By:
MNT Cholesterol News Health News
Sitagliptin And Simvastatin Combination - Juvisync - Approved By FDA For Diabetes With High Cholesterol http://mnt.to/429R #cholesterol
FDA Approves First Combo Drug for Diabetes Cholesterol - Diabetes - MSN Health
health.msn.com — “Juvisync combines Januvia and Zocor in one pill to lower blood sugar and bad cholesterol” View full resource at health.msn.com
Most Recently Shared on October 7, 2011 at 6:55 pm By:
FDA Approves First Combo Drug for Diabetes, Cholesterol: http://t.co/RmvIc3qs
FDA approves Merck's new diabetes therapy combo | Reuters
reuters.com — “(Reuters) - U.S. health regulators approved a new combination therapy for type 2 diabetes from Merck & Co, the first to combine a diabetes drug with cholesterol-lowering medicine in one tablet.Merck's” View full resource at reuters.com
Most Recently Shared on October 7, 2011 at 5:47 pm By:
FDA approves Merck's new diabetes therapy combo | Reuters: http://me.lt/582Df #pharma #diabetes
FDA approves Merck's new diabetes therapy combo - Yahoo! News
news.yahoo.com — “Read 'FDA approves Merck's new diabetes therapy combo' on Yahoo! News. (Reuters) - U.S. health regulators approved a new combination therapy for type 2 diabetes from Merck & Co, the first to combine a diabetes drug with cholesterol-lowering medicine in one tablet.” View full resource at news.yahoo.com
Most Recently Shared on October 7, 2011 at 5:31 pm By:
FDA approves Merck's new diabetes therapy combo: (Reuters) - U.S. health regulators approved a new combination ... http://t.co/0oSMOCJD
FDA approves Merck's new diabetes therapy combo | Reuters
reuters.com — “(Reuters) - U.S. health regulators approved a new combination therapy for type 2 diabetes from Merck & Co, the first to combine a diabetes drug with cholesterol-lowering medicine in one tablet.Merck's” View full resource at reuters.com
Most Recently Shared on October 7, 2011 at 5:30 pm By:
Brad Lipson, DO Doctor, Family Medicine Doctor, Physician, and Active Health Library
FDA approves Merck's new diabetes therapy combo: (Reuters) - U.S. health regulators approved a new combina... http://t.co/MP62xNKp
FDA Okays Combo Pill for Diabetes, Cholesterol - QualityPoint Technologies
qualitypointtech.net — “(MedPage Today) -- The FDA has approved a fixed-dose combination tablet that combines the diabetes drug sitagliptin with simvastatin, under the brand name Juvisync.” View full resource at qualitypointtech.net
Most Recently Shared on October 7, 2011 at 3:45 pm By:
FDA Okays Combo Pill for Diabetes, Cholesterol: (MedPage Today) -- The FDA has approved a fixed-dose combination t... http://t.co/gsHFod21
FDA Approves New HIV Treatment
medicalnewstoday.com — “The U.S. Food and Drug Administration approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy” View full resource at medicalnewstoday.com
Most Recently Shared on May 26, 2011 at 8:05 am By:
MNT Drug Approvals Health News
FDA Approves New HIV Treatment http://mnt.to/3WmX #regulatory
FDA Approves EDURANT™ (rilpivirine) For Use In Treatment-Naïve Adults With HIV-1 - QualityPoint Technologies
qualitypointtech.net — “The US Food and Drug Administration (FDA) approved EDURANTTM (rilpivirine) tablets for use in combination with other antiretroviral agents (ARVs) in the treatment of human immunodeficiency virus type 1 (HIV-1) in adults who have never taken HIV therapy (treatment naïve). EDURANT (pronounced ee' dur ant) was developed as TMC278 (rilpivirine) by Tibotec Pharmaceuticals and is a non-nucleoside reverse transcriptase inhibitor, or NNRTI...” View full resource at qualitypointtech.net
Most Recently Shared on May 21, 2011 at 9:45 am By:
FDA Approves EDURANT™ (rilpivirine) For Use In Treatment-Naïve Adults With HIV-1: The US Food and Drug Admini... http://bit.ly/mpJUNZ
Advertisement
